Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 7/20 | 0.36 |
| ▸ | CPS1 | P31327 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366059 | 1.00 | TOP2B (0.38) | TOP2BHTTKMT2AIDH1CPS1 | |
| SCHEMBL2366661 | 0.93 | PIK3CA (0.38) | TOP2BHTTKMT2AIDH1CPS1 | |
| SCHEMBL2366670 | 0.93 | PIK3CA (0.38) | TOP2BHTTKMT2AIDH1CPS1 | |
| SCHEMBL2365911 | 0.88 | KMT2A (0.38) | HTTKMT2AALDH1A1KDM4ECFTR | |
| SCHEMBL2365884 | 0.88 | KMT2A (0.38) | HTTKMT2AALDH1A1KDM4ECFTR | |
| SCHEMBL2366679 | 0.88 | TOP2B (0.37) | TOP2BHTTKMT2AIDH1CPS1 | |
| SCHEMBL2366685 | 0.88 | TOP2B (0.37) | TOP2BHTTKMT2AIDH1CPS1 | |
| SCHEMBL2366077 | 0.86 | HTT (0.40) | HTTKMT2AIDH1CPS1KDM4E | |
| SCHEMBL2366072 | 0.86 | HTT (0.40) | HTTKMT2AIDH1CPS1KDM4E | |
| Hydrochloric Acid SCHEMBL2546017 | 0.85 | HTT (0.39) | TOP2BHTTKMT2AIDH1CPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | TOP2B 2257/4885HTT 1580/4885KMT2A 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.